Stock Library / INSM

INSM Unclassified Latest YouTube: Q2 2026 Published 2026-08-06

INSM

Live stock metrics, chart context, a quarter-by-quarter episode archive, and a deeper competitor comparison so this page behaves more like an investor workspace than a flat episode link page.

Latest on YouTube Latest on Spotify Latest on Podbean Apple Podcasts Amazon Music iHeartRadio YouTube Music Company Website Back to Library

Latest earnings video

Insmed (INSM): The Revenue Beat Is Real. The Earnings Beat Is The Share Price.

Published 2026-08-06

Open YouTube Open Spotify Open Podbean Apple Podcasts

Library coverage

Episodes tracked

1

Episodes linked

1

Latest video

Q2 2026

2026-08-06

Podcast available

Yes

Current price

$132.55

+32.56 (+32.56%)

Trailing / Forward P/E

—

Forward: 1062.44x

Market cap / Volume

—

Volume: —

Revenue / Earnings Growth

229.6%

Earnings: —

Margins

-65.5% op

Gross: 81.8% · Net: -144.4%

Balance sheet

4.47x current

Debt / Equity: 105.3

52-week range / Beta

$90.39 - $212.75

Beta: 0.79

Analyst target

$195.95

Upside: 47.8%

Cash / shareholder return

-2.11% FCF yield

Dividend yield: —

Company context

Industry: Biotechnology

Country: United States

Employees: —

Price to book: 40.72x

Return on equity: -294.5%

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops INS1201, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as it is also developing pre-clinical research programs for gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. In addition, it provides INS1148, monoclonal antibody targeting stem cell factor called SCF248 that is in phase-2 clinical trial for the treatment of interstitial lung disease, and asthma; and INS1202, an intrathecally delivered gene therapy which is in phase 1 of clinical trial for the treatment of amyotrophic lateral sclerosis. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Price chart

Market context for INSM

Competitive view

INSM vs. two close competitors

This section compares the current company against two nearby peers on valuation, growth, margins, balance-sheet strength, and investment setup. Green generally marks the strongest relative figure for that row, while red marks the weakest.

INSM latest YouTube video thumbnail

INSM

INSM

YouTube Spotify Podbean

Latest video

Q2 2026

Growth profile looks strong right now, with above-average top-line and/or earnings momentum.

Profitability is serviceable, but it does not obviously dominate peers on margin or cash conversion alone.

Valuation already asks investors to pay up, so the upside case depends on continued execution staying strong.

Balance-sheet leverage is elevated, so investors should watch refinancing costs and how much flexibility management really has.

SS&C Technologies Holdings Inc. latest YouTube video thumbnail

SS&C Technologies Holdings Inc.

SSNC

YouTube Podbean

Latest video

Q2 2026

Growth profile looks strong right now, with above-average top-line and/or earnings momentum.

Cash generation stands out versus market value, which helps the stock absorb valuation pressure better than weaker cash converters.

Valuation looks more grounded than many growth names, which can improve the risk/reward if fundamentals hold up.

Balance-sheet leverage is elevated, so investors should watch refinancing costs and how much flexibility management really has.

Palantir Technologies latest YouTube video thumbnail

Palantir Technologies

PLTR

YouTube Podbean

Latest video

Q2 2026

Growth profile looks strong right now, with above-average top-line and/or earnings momentum.

Profitability is a real strength here, with healthy operating margins helping support resilience through weaker cycles.

Valuation already asks investors to pay up, so the upside case depends on continued execution staying strong.

Expect a more volatile ride than the market average; that can amplify upside, but drawdowns can come fast too.

Market Cap

More scale can mean deeper resources and resilience, although bigger does not automatically mean better upside.

INSM

$28.73B

INSM

SSNC

$18.73B

SS&C Technologies Holdings Inc.

PLTR

$374.68B

Palantir Technologies

Trailing P/E

Lower trailing P/E can indicate a cheaper valuation relative to trailing earnings, but it may also reflect slower growth or higher perceived risk.

INSM

—

INSM

SSNC

22.9x

SS&C Technologies Holdings Inc.

PLTR

175.2x

Palantir Technologies

Forward P/E

Forward P/E is often a better read on what investors are paying for the next year of earnings power.

INSM

1062.4x

INSM

SSNC

10.3x

SS&C Technologies Holdings Inc.

PLTR

68.9x

Palantir Technologies

Revenue Growth

Higher revenue growth usually signals stronger demand, market share gains, or a business still in expansion mode.

INSM

229.6%

INSM

SSNC

10.3%

SS&C Technologies Holdings Inc.

PLTR

92.8%

Palantir Technologies

Earnings Growth

Faster earnings growth matters because it shows management is converting sales momentum into shareholder value.

INSM

—

INSM

SSNC

34.7%

SS&C Technologies Holdings Inc.

PLTR

215.4%

Palantir Technologies

Operating Margin

Higher operating margin suggests better operating discipline, pricing power, or a structurally stronger business model.

INSM

-65.5%

INSM

SSNC

24.6%

SS&C Technologies Holdings Inc.

PLTR

47.1%

Palantir Technologies

Gross Margin

Gross margin helps show how much product-level pricing power and unit economics a company has before overhead.

INSM

81.8%

INSM

SSNC

48.1%

SS&C Technologies Holdings Inc.

PLTR

84.8%

Palantir Technologies

Net Margin

Higher net margin means more of each dollar of revenue reaches the bottom line after all costs.

INSM

-144.4%

INSM

SSNC

13.2%

SS&C Technologies Holdings Inc.

PLTR

49.0%

Palantir Technologies

Return on Equity

ROE shows how efficiently management turns shareholder capital into profits, though leverage can inflate it.

INSM

-294.5%

INSM

SSNC

12.6%

SS&C Technologies Holdings Inc.

PLTR

38.1%

Palantir Technologies

Free Cash Flow Yield

Higher free cash flow yield can indicate a stronger cash return relative to the stock's market value.

INSM

-2.1%

INSM

SSNC

7.0%

SS&C Technologies Holdings Inc.

PLTR

0.6%

Palantir Technologies

Debt to Equity

Lower leverage usually means less balance-sheet risk, though capital-intensive sectors naturally run higher debt loads.

INSM

105.34x

INSM

SSNC

115.90x

SS&C Technologies Holdings Inc.

PLTR

2.14x

Palantir Technologies

Current Ratio

A stronger current ratio usually signals better short-term liquidity and more room to absorb shocks.

INSM

4.47x

INSM

SSNC

1.06x

SS&C Technologies Holdings Inc.

PLTR

7.23x

Palantir Technologies

Beta

Lower beta often means lower volatility versus the market, while higher beta usually brings a rougher ride.

INSM

0.79

INSM

SSNC

1.09

SS&C Technologies Holdings Inc.

PLTR

1.56

Palantir Technologies

Dividend Yield

Dividend yield matters for income-focused investors, but a high yield can also reflect a stressed stock price.

INSM

—

INSM

SSNC

1.4%

SS&C Technologies Holdings Inc.

PLTR

—

Palantir Technologies

Analyst Upside

Higher analyst upside suggests the Street still sees room between current price and consensus fair value.

INSM

47.8%

INSM

SSNC

15.6%

SS&C Technologies Holdings Inc.

PLTR

21.1%

Palantir Technologies

Related research

Non-quarter videos featuring INSM

Special-topic videos, explainers, and shorts connected to this ticker.

All Research Sections

Shorts and Clips 2026-08-06

INSM: 88% Of The Earnings Beat Was Its Own Stock Falling

A fast Charged Alpha clip pointing viewers into the latest earnings coverage.

YouTube

Episode timeline

Episode archive for INSM

Each row is one earnings episode with every verified platform link available.

Q2 2026

Episode live

2026-08-06

Published youtube podcast complete

Insmed (INSM): The Revenue Beat Is Real. The Earnings Beat Is The Share Price.

Quarterly earnings-analysis entry for INSM. Use the links on the right to open the video or podcast episode.

YouTube Spotify Podcast Apple Podcasts Amazon Show iHeart Show YouTube Music